138 related articles for article (PubMed ID: 29845459)
1. Synthesis, Characterization and Biocompatibility of N-palmitoyl L-alanine-based Organogels as Sustained Implants of Granisetron and Evaluation of thier Antiemetic Effect.
El-Nassan HB; ElMeshad AN; Wadie W; Sayed RH
Pharm Res; 2018 May; 35(8):149. PubMed ID: 29845459
[TBL] [Abstract][Full Text] [Related]
2. Involvement of substance P in the development of cisplatin-induced acute and delayed pica in rats.
Yamamoto K; Asano K; Tasaka A; Ogura Y; Kim S; Ito Y; Yamatodani A
Br J Pharmacol; 2014 Jun; 171(11):2888-99. PubMed ID: 24641692
[TBL] [Abstract][Full Text] [Related]
3. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.
Campos D; Pereira JR; Reinhardt RR; Carracedo C; Poli S; Vogel C; Martinez-Cedillo J; Erazo A; Wittreich J; Eriksson LO; Carides AD; Gertz BJ
J Clin Oncol; 2001 Mar; 19(6):1759-67. PubMed ID: 11251007
[TBL] [Abstract][Full Text] [Related]
4. Characterization and biocompatibility of organogels based on L-alanine for parenteral drug delivery implants.
Motulsky A; Lafleur M; Couffin-Hoarau AC; Hoarau D; Boury F; Benoit JP; Leroux JC
Biomaterials; 2005 Nov; 26(31):6242-53. PubMed ID: 15916802
[TBL] [Abstract][Full Text] [Related]
5. First report on the efficacy of l-alanine-based in situ-forming implants for the long-term parenteral delivery of drugs.
Plourde F; Motulsky A; Couffin-Hoarau AC; Hoarau D; Ong H; Leroux JC
J Control Release; 2005 Nov; 108(2-3):433-41. PubMed ID: 16182402
[TBL] [Abstract][Full Text] [Related]
6. In situ-forming pharmaceutical organogels based on the self-assembly of L-alanine derivatives.
Couffin-Hoarau AC; Motulsky A; Delmas P; Leroux JC
Pharm Res; 2004 Mar; 21(3):454-7. PubMed ID: 15070096
[TBL] [Abstract][Full Text] [Related]
7. Granisetron Extended-Release Injection: A Review in Chemotherapy-Induced Nausea and Vomiting.
Deeks ED
Drugs; 2016 Dec; 76(18):1779-1786. PubMed ID: 27915445
[TBL] [Abstract][Full Text] [Related]
8. A double-blind, crossover, randomized dose-comparison trial of granisetron for the prevention of acute and delayed nausea and emesis in children receiving moderately emetogenic carboplatin-based chemotherapy.
Berrak SG; Ozdemir N; Bakirci N; Turkkan E; Canpolat C; Beker B; Yoruk A
Support Care Cancer; 2007 Oct; 15(10):1163-8. PubMed ID: 17372773
[TBL] [Abstract][Full Text] [Related]
9. APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy.
Schnadig ID; Agajanian R; Dakhil C; Gabrail NY; Smith RE; Taylor C; Wilks ST; Schwartzberg LS; Cooper W; Mosier MC; Payne JY; Klepper MJ; Vacirca JL
Future Oncol; 2016 Jun; 12(12):1469-81. PubMed ID: 26997579
[TBL] [Abstract][Full Text] [Related]
10. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy.
Gralla RJ; Navari RM; Hesketh PJ; Popovic W; Strupp J; Noy J; Einhorn L; Ettinger D; Bushnell W; Friedman C
J Clin Oncol; 1998 Apr; 16(4):1568-73. PubMed ID: 9552067
[TBL] [Abstract][Full Text] [Related]
11. Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy.
Gurpide A; Sadaba B; Martin-Algarra S; Azanza JR; Lopez-Picazo JM; Campanero MA; Cabello JP; Gil-Aldea I; de la Cruz S; Fernandez Gallego V; Reyna C; Olier Garate C; Blanco-Prieto MJ; Ceballos J; Garcia-Foncillas J; Perez-Gracia JL
Oncologist; 2007 Sep; 12(9):1151-5. PubMed ID: 17914085
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
13. Self-assembled L-alanine derivative organogel as in situ drug delivery implant: characterization, biodegradability, and biocompatibility.
Wang K; Jia Q; Han F; Liu H; Li S
Drug Dev Ind Pharm; 2010 Dec; 36(12):1511-21. PubMed ID: 21050137
[TBL] [Abstract][Full Text] [Related]
14. Granisetron: relating pharmacology to clinical efficacy.
Blower PR
Support Care Cancer; 2003 Feb; 11(2):93-100. PubMed ID: 12560937
[TBL] [Abstract][Full Text] [Related]
15. Antiemetic role of thalidomide in a rat model of cisplatin-induced emesis.
Han ZX; Xu J; Wang HM; Ma J; Sun X; Du XP
Cell Biochem Biophys; 2014 Sep; 70(1):361-5. PubMed ID: 24718779
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, crossover, randomized comparison of granisetron and ramosetron for the prevention of acute and delayed cisplatin-induced emesis in patients with gastrointestinal cancer: is patient preference a better primary endpoint?
Koizumi W; Tanabe S; Nagaba S; Higuchi K; Nakayama N; Saigenji K; Nonaka M; Yago K
Chemotherapy; 2003 Dec; 49(6):316-23. PubMed ID: 14671433
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of clinical effects between granisetron alone and combination of granisetron and methylprednisolone against the nausea and vomiting induced by CDDP chemotherapy--comparative study by the cross-over trial. University of Tsukuba Antiemetics Study Group].
Uchida K; Akaza H; Shimazui T; Kikuchi K; Manabe F; Iwasaki A; Ishikawa S; Noguchi R; Otani M; Hattori K; Kondo F; Nishijima Y; Sato K; Koiso K; Hinotsu S
Gan To Kagaku Ryoho; 1996 Jan; 23(1):81-6. PubMed ID: 8546475
[TBL] [Abstract][Full Text] [Related]
18. Provesicular granisetron hydrochloride buccal formulations: in vitro evaluation and preliminary investigation of in vivo performance.
Ahmed S; El-Setouhy DA; El-Latif Badawi AA; El-Nabarawi MA
Eur J Pharm Sci; 2014 Aug; 60():10-23. PubMed ID: 24793896
[TBL] [Abstract][Full Text] [Related]
19. Self-assembled drug delivery system based on low-molecular-weight bis-amide organogelator: synthesis, properties and in vivo evaluation.
Li Z; Cao J; Li H; Liu H; Han F; Liu Z; Tong C; Li S
Drug Deliv; 2016 Oct; 23(8):3168-3178. PubMed ID: 26912188
[TBL] [Abstract][Full Text] [Related]
20. Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin.
Matsui K; Fukuoka M; Takada M; Kusunoki Y; Yana T; Tamura K; Yoshida T; Iida K; Hirashima T; Tsukada H; Ushijima S; Miyawaki H; Masuda N
Br J Cancer; 1996 Jan; 73(2):217-21. PubMed ID: 8546909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
